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amoxicillin at least once was 1,284 before the letter and 1,521 after the letter. For cefaclor, the numbers of patients were 1,141 (before the letter) and 1,886 (after the letter), respectively.
Study design
A time-series design was used to identify the temporal relationship between the effects of the HIC letter on patient outcomes and prescription share (i.e. the percentage of the antibiotics ordered when compared with other antibiotics in connection with an episode of sinusitis, OM, LRTI or AECB). To assess how representative the patients were of the Australian population, the age and gender profiles of the database patient sample were compared with the national Australian general practice attendees for the middle year of the study, 1997. The study period was 1994 to 1998.
Analysis of effectiveness
All of the patients included in the study were accounted for at analysis. Both patient outcomes and process-of-care outcomes were considered in the study. The patient outcomes included uninitiated return visits to the GP within 2 weeks of receiving the antibiotic, hospitalisation, and referral to a specialist. The process-of-care outcomes included computed tomography scan of sinus and chest, chest radiography, and pathology tests, spirometry, bronchoscopy and sinoscopy. An outcome was considered to be related to a specific antibiotic if it occurred within the EOC in which the antibiotic was prescribed.
The overall patient sample and the national Australian general practice attendees were comparable in age and gender profiles.
Effectiveness results
There were 1,854 adverse outcomes in the period before the letter, and 3,271 in the period after the letter.
The rate of patient and process-of-care outcomes per 100 EOC remained the same for amoxicillin, at 3.8 before and after the letter. The rate changed from 9.3 to 11.5 for macrolides, from 6.9 to 7.1 for cefaclor, from 9.0 to 9.6 for cephalexin, and from 7.9 to 11.3 for AC.
Of all EOCs that involved AC before the letter, 0.14 per 100 EOCs had a hospitalisation. Of all EOCs that involved AC after the letter, 1.84 per 100 EOCs had a hospitalisation, (p=0.0011).
For the EOCs in which the macrolides cefaclor, cephalexin and amoxicillin were given alone, there were no significant changes in the rate of each outcome.
When all EOCs for which at least two of these antibiotics were given as a total group were analysed, there were significant increases in the rate of adverse outcomes per 100 other antibiotic-related EOCs for the following: hospitalisation, 0.44 before the letter and 0.86 after the letter, (p=0.0054); radiologic investigations, 3.27 before the letter and 4.87 after the letter, (p=0.00001); and pathologic investigations, 2.73 before the letter and 3.62 after the letter, (p=0.005489).
There was a significant association between the increase in the rate per month for all outcomes and the decrease in ACprescription share, (p=0.011), with a 3-month lag.
There was also a significant association between AC-prescription share and the overall outcome rate weighted by relative cost, (p=0.0024).
The rate of patient outcomes, including return visits, was not significantly associated with AC-prescription share.
The rate of process-of-care outcomes was significantly associated with AC-prescription share also at the 3-month lag, (p=0.006).
